Welcome to our dedicated page for Innate Pharma Sa news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma Sa stock.
Innate Pharma S.A. (IPHA) news covers the company’s progress as a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. As a dual-listed issuer on Euronext Paris (IPH) and Nasdaq (IPHA), Innate Pharma regularly publishes regulatory and corporate updates that are relevant to investors following immuno-oncology and antibody-based therapeutics.
News about Innate Pharma frequently highlights developments across its antibody-engineering and ANKET® (Antibody-based NK cell Engager Therapeutics) platform. Company releases describe clinical and regulatory milestones for key assets such as IPH4502, a differentiated Nectin-4 ADC in solid tumors; lacutamab, a first-in-class anti-KIR3DL2 monoclonal antibody in cutaneous and peripheral T cell lymphomas; and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer.
Investors can expect updates on clinical trial progress, including Phase 1, Phase 2 and Phase 3 studies, regulatory designations for pipeline assets, and collaboration news involving partners such as Sanofi and AstraZeneca. Innate Pharma’s news flow also includes financial communications, such as business updates, financial results, financial calendars, and regulatory disclosures on the number of shares outstanding and voting rights under French market rules.
This news page aggregates these company communications in one place, making it easier to follow Innate Pharma’s clinical pipeline evolution, partnership activities and key corporate events. Readers interested in immuno-oncology, antibody-drug conjugates, NK cell engagers and collaboration-driven biotech models can use this feed to monitor how Innate Pharma reports its progress over time.
Innate Pharma (NASDAQ:IPHA) has released its updated share capital and voting rights information as of August 1, 2025. The company reported 92,184,823 ordinary shares outstanding, along with 6,424 Preferred Shares 2016 and 7,581 Preferred Shares 2017.
The company's total theoretical voting rights stand at 92,962,943, while exercisable voting rights amount to 92,944,368. This disclosure is made in compliance with French regulatory requirements and AMF recommendations.
Innate Pharma (NASDAQ:IPHA) announced its participation in the upcoming BTIG Virtual Biotechnology Conference scheduled for July 29-30, 2025. The company's CEO Jonathan Dickinson and COO Yannis Morel will represent Innate at the event.
The company will participate in a Fireside chat on Wednesday July 30 at 2:00 PM EST, followed by one-on-one meetings. Notably, BTIG, which recently initiated analyst coverage of Innate Pharma, is hosting this conference as part of their global financial services offerings.
Innate Pharma (NASDAQ:IPHA) has disclosed its updated share capital and voting rights structure as of July 3, 2025. The company reported 92,183,523 ordinary shares outstanding, along with 6,434 Preferred Shares 2016 and 7,581 Preferred Shares 2017.
The total number of theoretical voting rights stands at 92,962,943, while exercisable voting rights amount to 92,944,368. This disclosure is made in compliance with French regulatory requirements and AMF recommendations.
Innate Pharma (NASDAQ: IPHA) has announced its participation in multiple upcoming healthcare conferences in June 2025. The company's executive team will present at the Jefferies Global Healthcare Conference in New York (June 3-5), with a fireside chat scheduled for June 5 at 7:35 am EDT. They will also participate in the Goldman Sachs 46th Annual Global Healthcare Conference in Miami (June 9-11), with a fireside chat set for June 10 at 4:00 pm EDT.
Additionally, the executive team will attend the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 30 to June 3, 2025.
Innate Pharma (IPHA) held its Annual General Meeting on May 22, 2025, where shareholders approved all resolutions with a quorum of 47.14%. The key highlight was the company's transition from an Executive Board and Supervisory Board structure to a Board of Directors structure with a Chief Executive Officer.
The newly formed Board includes eight members, with Mrs. Irina Staatz-Granzer appointed as Chairman of the Board and Mr. Jonathan Dickinson as Chief Executive Officer, marking a separation of these two key roles. This governance change aims to align the company with international standards.
Innate Pharma (NASDAQ: IPHA) announced the selection of four abstracts featuring its clinical development drugs for presentation at the ASCO 2025 Annual Meeting (May 30-June 3, 2025). The presentations include long-term follow-up data from the TELLOMAK Phase 2 trial studying lacutamab in Sézary syndrome and mycosis fungoides patients, a trial in progress poster for IPH4502 in advanced solid tumors expressing Nectin-4, and AstraZeneca's poster on updated results from the NeoCOAST-2 Phase 2 trial of monalizumab in resectable non-small-cell lung cancer (NSCLC).
Innate Pharma (NASDAQ: IPHA) announced the selection of abstracts for presentation at the European Hematology Association (EHA) Congress 2025 in Milan, Italy. The first abstract features IPH6501, their ANKET® therapy targeting CD20 B cells for relapsed/refractory Non-Hodgkin Lymphoma, which will be presented in a poster session on June 14, 2025. Additionally, an abstract about SAR'514/IPH6401, developed in partnership with Sanofi for Multiple Myeloma treatment, was accepted for online publication.